Considering that knocking down STAG2 in BRAF-mutant melanoma cells significantly decreased their sensitivity to BRAF/MEK inhibitors [15], we thus attempted to determine whether STAG2 knockdown affected the response of BRAF-mutant thyroid cancer cells to BRAF/MEK inhibitors. This evidence concerns the gene STAG2 and melanoma.